Clinical Trial Update: ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors

View source ↗

Summary

ESPERANZA is an external control arm study of trastuzumab deruxtecan (T-DXd) for patients with HER2 IHC3+ solid tumors, sponsored by AstraZeneca. The trial stat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Bladder Cancer
• Cervical Cancer
• Colorectal Cancer
• Endometrial Cancer
• Lung Cancer
• Ovarian Cancer
• Pancreatic Cancer

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)

Snippet

Sponsor: AstraZeneca | Conditions: Bladder Cancer, Biliary Tract Cancer | Status: COMPLETED